Country: New Zealand
Language: English
Source: Medsafe (Medicines Safety Authority)
Influenza virus A/Darwin/9/2021 (H3N2)-like strain 15ug (A/Darwin/9/2021, SAN 010); Influenza virus A/Sydney/5/2021 (H1N1) pdm09-like strain 15ug (A/Sydney/5/2021, SAN 013); Influenza virus B/Austria/1359417/2021-like strain 15ug (B/Austria/1359417/2021, BVR-26); Influenza virus B/Phuket/3073/2013 - like strain 15ug (B/Phuket/3073/2013, wild type)
Viatris Limited
Influenza virus A/Michigan/45/2015 (H1N1) pdm09 - like strain 15 µg (A/Singapore/GP1908/2015, IVR-180)
0.5 mL
Suspension for injection
Active: Influenza virus A/Darwin/9/2021 (H3N2)-like strain 15ug (A/Darwin/9/2021, SAN 010) Influenza virus A/Sydney/5/2021 (H1N1) pdm09-like strain 15ug (A/Sydney/5/2021, SAN 013) Influenza virus B/Austria/1359417/2021-like strain 15ug (B/Austria/1359417/2021, BVR-26) Influenza virus B/Phuket/3073/2013 - like strain 15ug (B/Phuket/3073/2013, wild type) Excipient: Calcium chloride dihydrate Dibasic sodium phosphate as dihydrate 0.67 mg Magnesium chloride hexahydrate Monobasic potassium phosphate Potassium chloride Sodium chloride Water for injection
Prescription
Abbott Biologicals BV
For the prevention of influenza caused by influenza virus, types A and B. For full details regarding recommendations for influenza vaccination, please refer to the relevant National Immunisation Guidelines. Influvac Tetra is indicated in adults and children from 6 months of age and older.
Package - Contents - Shelf Life: Syringe, glass, Pre-filled 0.5 mL - 1 dose units - 12 months from date of manufacture stored at 2° to 8°C (Refrigerate, do not freeze) protect from light - Syringe, glass, Pre-filled 0.5 mL - 10 dose units - 12 months from date of manufacture stored at 2° to 8°C (Refrigerate, do not freeze) protect from light
2016-08-16
Page 1 of 3 NEW ZEALAND CONSUMER MEDICINE INFORMATION INFLUVAC ® TETRA _INACTIVATED INFLUENZA VACCINE_ _SUSPENSION FOR INJECTION 60 MICROGRAM PER 0.5 ML_ WHAT IS IN THIS LEAFLET This leaflet answers some common questions about Influvac Tetra. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have risks and benefits. Your doctor has weighed the risks of you having Influvac Tetra against the benefits they expect it will have for you. IF YOU HAVE ANY CONCERNS ABOUT BEING GIVEN THIS MEDICINE, ASK YOUR DOCTOR OR PHARMACIST. KEEP THIS LEAFLET WITH THE MEDICINE. You may need to read it again. WHAT INFLUVAC TETRA IS USED FOR Influvac Tetra is used to prevent certain types of influenza (commonly called flu). The vaccine works by causing the body to produce its own protection (antibodies) against four different types of influenza virus. Each year new types of influenza virus can appear, so every year Influvac Tetra is changed to contain fragments of the new types of virus. Therefore, influenza vaccination is recommended every year. PLEASE NOTE THAT INFLUVAC TETRA WILL ONLY PROTECT YOU AGAINST THE FOUR TYPES OF INFLUENZA VIRUS USED TO MAKE THE VACCINE. IT WILL NOT PROTECT YOU FROM INFLUENZA CAUSED BY OTHER TYPES OF INFLUENZA VIRUS OR FROM INFECTIONS WITH OTHER AGENTS CAUSING FLU-LIKE SYMPTOMS (SUCH AS THE COMMON COLD). Influenza is an infectious illness. Influenza is spread by small droplets from the nose, throat or mouth of an infected person. Symptoms of influenza begin 48 hours after coming into contact with the virus. These consist of chills, fever, generalised aches and pains, headache and respiratory symptoms (sore throat, runny nose, cough). The severity and type of symptoms can vary. Most people recover completely within a week. The risk of serious complications (e.g. pneumonia and death) is greater in very young, very old and chronically ill persons. Influvac Tetra can be used in adults and in children over the age of 3 years. For f Read the complete document
Page 1 of 8 NEW ZEALAND DATA SHEET INFLUVAC ® TETRA 1. PRODUCT NAME Influvac Tetra, 60 microgram haemagglutinin per 0.5 mL, Suspension for injection. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Influvac Tetra is a purified, inactivated influenza vaccine (surface antigen), containing the following four influenza strains recommended for the 2021 influenza season: A/Victoria/2570/2019 (H1N1)pdm09-like strain (A/Victoria/2570/2019, IVR-215) A/Hong Kong/2671/2019 (H3N2)-like strain (A/Hong Kong/2671/2019, IVR-208) B/Washington/02/2019-like strain (B/Victoria lineage) (B/Washington/02/2019, wild type) B/Phuket/3073/2013-like strain (B/Yamagata lineage) (B/Phuket/3073/2013, wild type) Each 0.5 mL dose contains 15 micrograms haemagglutinin per each of the above mentioned viral strains, for a combined total of 60 micrograms. Each strain has been propagated in fertilised hens’ eggs from healthy chickens. The type and amount of viral antigens in Influvac Tetra conform to the requirements of the Australian Influenza Vaccine Committee (AIVC) and the New Zealand Ministry of Health for the 2021 southern hemisphere influenza season. For a full list of excipients, see section 6.1. Influvac Tetra antigens have been produced from eggs and are inactivated by formaldehyde treatment. Each 0.5 mL may also contain not more than 100 nanograms ovalbumin, 0.01 mg formaldehyde, 0.02 mg cetrimonium bromide, 1 mg sodium citrate, 0.2 mg sucrose, 1 nanograms gentamicin sulfate, traces of tylosine tartrate, hydrocortisone and polysorbate 80 which are used during the manufacturing process. 3. PHARMACEUTICAL FORM Influvac Tetra is a clear colourless liquid for injection in pre-filled syringes. 4. CLINICAL PARTICULARS _4.1 _ _THERAPEUTIC INDICATIONS_ For the prevention of influenza caused by influenza virus, types A and B. Page 2 of 8 For full details regarding recommendations for influenza vaccination, please refer to the relevant National Immunisation Guidelines. Influvac Tetra is indicated in adults and children from 3 years o Read the complete document